In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Effect of hypertrophy degree and fibrosis on regional contractile function in left ventricular hypertrophy

Session Poster session 1

Speaker Natalia Cobo Gomez

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance: Deformation Imaging
  • Session type : Poster Session
  • FP Number : P159

Authors : N Cobo Gomez (Sevilla,ES)

Authors:
N Cobo Gomez1 , 1Sagrado Corazón, Quirón Salud, Cardiology - Sevilla - Spain ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii115

INTRODUCTION
Regional contractile dysfunction is a frequent finding in hypertrophic cardiomyopathy ( HCM) and fenocopies. Previous studies predominantly performed with echocardiography speckle tracking have shown that there is widespread variation in myocardial contractility throughout the ventricle in left ventricular hypertrophy related to the extent of hypertrophy and presence of replacement fibrosis. Alternative method to echocardiography for the assessment of regional strain is cardiovascular magnetic resonance (CMR) post processing feature tracking (FT).
PURPOSE.
We aimed to investigate the contribution of different tissue characteristics in left ventricular hypertrophy to regional contractile dysfunction.
METHODS
We prospectively recruited 60 patients with left ventricular hypertrophy  who underwent CMR studies at 1.5 T including cine imaging and late gadolinium enhancement (LGE) imaging. For each segment of the American Heart Association model segment thickness, presence of LGE and regional strain (by FT) were assessed. The relationship of segmental function, hypertrophy and tissue characteristics were determined using a mixed effects model, with random intercept for each patient.
RESULTS
Univariate analysis showed statistically significant association of individually segment thickness and the presence of LGE with regional strain parameters.
The multivariable model ( segment thickness and LGE) demonstrated that all strain  parameters were associated with both segment thickness (P < 0.05 for all) and LGE (p < 0.05 for all). Table 1. 
CONCLUSION
Impairment of contractile function in left ventricular hypertrophy is associated with the degree of hypertrophy and extracellular fibrosis ( LGE).

LGE

Segment thickness

Beta (CI95%)

p-value

Beta (CI95%)

p-value

Longitudinal

Univariant

2,768 (0,932; 4,603)

0,003

0,363 (0,182; 0,543)

<0,001

Multivariant

2,444 (0,599; 4,288)

0,01

0,336 (0,152; 0,521)

<0,001

Radial

Univariant

-25,376 (-33,809; -16,942)

<0,001

-4,994 (-5,814; -4,174)

<0,001

Multivariant

-10,279 (-18,886; -1,671)

0,019

-4,669 (-5,517; -3,822)

<0,001

Circunferencial

Univariant

4,945 (3,398; 6,493)

<0,001

0,611 (0,459; 0,762)

<0,001

Multivariant

3,859 (2,347; 5,370)

<0,001

0,538 (0,387;0,689)

<0,001

Mixed effects model, with random intercept for each patient assessing the association between regional strain and the tissue characteristics of each segment.


Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are